Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 6/20 | 0.52 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.51 |
| ▸ | EP300 | Q09472 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13623430 | 0.84 | FGFR1 (0.51) | PKMFGFR1SLC22A6EP300LMNA | |
| SCHEMBL25521527 | 0.83 | FGFR1 (0.71) | PKMFGFR1SLC22A6EP300LMNA | |
| SCHEMBL15046004 | 0.83 | FGFR1 (0.71) | PKMFGFR1SLC22A6EP300LMNA | |
| SCHEMBL12652844 | 0.79 | FGFR1 (0.51) | FGFR1SLC22A6EP300LMNATHRB | |
| SCHEMBL24420265 | 0.78 | FGFR1 (0.48) | FGFR1SLC22A6EP300LMNATHRB | |
| SCHEMBL16197895 | 0.78 | FGFR1 (0.48) | FGFR1SLC22A6EP300LMNATHRB | |
| SCHEMBL24420129 | 0.78 | FGFR1 (0.48) | FGFR1SLC22A6EP300LMNATHRB | |
| SCHEMBL14478248 | 0.78 | FGFR1 (0.50) | FGFR1SLC22A6 | |
| SCHEMBL140792 | 0.77 | FGFR1 (0.50) | FGFR1SLC22A6EP300LMNATHRB | |
| SCHEMBL18069556 | 0.77 | FGFR1 (0.50) | FGFR1SLC22A6EP300LMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933012-B2 | Glycopeptide antibiotic derivative | SHIONOGI & CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-20090286717-A1 | Glycopeptide Antibiotic Derivative | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| CN-101501064-A | Glycopeptide Antibiotic Derivatives | SHIONOGI & CO (JP) | 2009-08-05 | — | — | CN | disclosed |
| EP-2030982-A1 | GLYCOPEPTIDE ANTIBIOTIC DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2009-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286717-A1 | Glycopeptide Antibiotic Derivative | NR2C2, NR0B2, NR3C2 | PKM 4406/4885FGFR1 788/4885SLC22A6 1226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.